XML 9 R2.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 23,367 $ 50,482
Accounts receivable, net 136 481
Inventories 3,863 3,155
Prepaid expenses and other current assets 2,306 31,542
Current assets held for sale 132,650 110,849
Total current assets 162,322 196,509
Other assets 839 1,405
Long-term assets held for sale 14,894 16,611
Total assets 178,055 214,525
Current liabilities:    
Accounts payable 10,477 5,064
Accrued and other current liabilities 35,916 62,035
Deferred revenue 27,311 27,290
Senior secured term loan facilities, current 73,733 0
Current liabilities held for sale 8,458 38,917
Total current liabilities 155,895 133,306
Product development obligations 19,398 17,012
Deferred revenue, net of current 122,224 114,708
Senior secured term loan facilities, non-current 0 73,092
Liability related to sale of future revenues, non-current 61,306 58,864
Other long-term liabilities 106 822
Long-term liabilities held for sale 156 356
Total liabilities 359,085 398,160
Commitments and Contingencies
Redeemable non-controlling interests 21,480 21,480
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2025 and December 31, 2024
Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2025 and December 31, 2024; 4,044 and 4,037 shares issued outstanding at June 30, 2025 and December 31, 2024 1,011 1,009
Additional paid-in capital 1,673,249 1,668,620
Accumulated other comprehensive loss (4,794) (5,732)
Accumulated deficit (1,892,463) (1,889,499)
Total stockholders' deficit attributable to FibroGen (222,997) (225,602)
Nonredeemable non-controlling interests 20,487 20,487
Total deficit (202,510) (205,115)
Total liabilities, redeemable non-controlling interests and deficit $ 178,055 $ 214,525